AMENDMENTS IN THE CLAIMS

- 1. (previously presented) A method of inducing an immune response by administration of a recombinant immunogen comprising a fusion protein of an antigen fused to the A2 and B subunits of a type II heat-labile enterotoxin, wherein said immune response is selected from the group consisting of development of antigen-specific T cells in the circulation and tissues, the development of cytotoxic T cells and immunological tolerance to the antigen sequence.
- 2. (original) The method of claim 1, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).
- 3. (original) The method of claim 1, wherein said type II heat-labile enterotoxin is selected from the group consisting of *E. coli* heat-labile type IIa toxin and *E. coli* heat-labile type IIb toxin.
 - 4-5. (canceled)

6. (original) The method of claim 1, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, intravaginally, intramuscularly, transcutaneously and subcutaneously.

7-23. (canceled)

- 24. (previously presented) A method of increasing Th1 response and cell-mediated immunity by administration of a recombinant immunogen comprising a fusion protein of an antigen fused to the A2 and B subunits of a type II heat-labile enterotoxin.
- 25. (original) The method of claim 24, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).
- 26. (original) The method of claim 24, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, intravaginally, intramuscularly, transcutaneously and subcutaneously.

- 27. (previously presented) A method of increasing Th1 response and cell-mediated immunity by administration of a recombinant immunogen comprising a fusion protein of an antigen fused to the A2 and B subunits of a *E. coli* heat-labile type IIa or type IIb toxin.
- 28. (original) The method of claim 27, wherein said antigen of interest is salivary binding protein (SBR) from *Streptococcus mutans* surface protein (Ag I/II).
- 29. (original) The method of claim 27, wherein said immunogen is administered by a route selected from the group consisting of orally, intranasally, intrarectally, intravaginally, intramuscularly, transcutaneously and subcutaneously.